{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:23:02Z","timestamp":1791922982833,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Interindividual variability in metabolic dysfunction\u2013associated steatotic liver disease (MASLD) onset and its progressive inflammatory stage, metabolic dysfunction\u2013associated steatohepatitis (MASH), reflects a complex interplay between metabolic burden and inherited susceptibility. We investigated the combined impact of genetic variants in the glucokinase regulatory protein gene (GCKR) and fibroblast growth factor 21 (FGF21), together with circulating FGF21 concentrations, on susceptibility to MASLD and its progression to MASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This case-control study enrolled 150 patients with MASLD, 150 patients with clinically suspected MASH, and 150 age- and sex-matched healthy controls. Genotyping of GCKR\n                      <jats:italic>rs1260326<\/jats:italic>\n                      and FGF21\n                      <jats:italic>rs838133<\/jats:italic>\n                      polymorphisms was performed using DNA extracted from peripheral blood samples by real-time polymerase chain reaction, while serum FGF21 levels were quantified by enzyme-linked immunosorbent assay. Associations with metabolic characteristics, liver function indices, and fibrosis severity were examined using correlation analyses and multivariate logistic regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The GCKR rs1260326 TT genotype and T allele carriers had an increased risk of MASH progression versus MASLD (AOR for TT genotype: 16.875; 95% CI: 6.339\u201344.921,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), adjusted for age, sex, BMI, HOMA-IR and triglycerides level. Moreover, the TT genotype was associated with higher alanine aminotransferase levels and reduced markers of hepatic synthetic capacity. In parallel, carriers of AG genotype of FGF21 rs838133 exhibited a higher propensity for progression to MASLD (AOR: 18.622; 95% CI: 1.619-214.169,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.019) and G allele accompanied by greater insulin resistance and unfavorable lipid profiles. Circulating FGF21 concentrations demonstrated a stepwise increase from controls to MASLD and MASH groups and showed good discriminatory performance in differentiating MASLD from controls (AUC\u2009=\u20090.821) and excellent accuracy in identifying MASH among healthy individuals (AUC\u2009=\u20090.929).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genetic variation in GCKR and FGF21, together with altered hepatokine signaling, contributes substantially to metabolic dysregulation and liver disease severity. Integrating genetic profiling with circulating biomarkers may offer a refined strategy for identifying individuals at high risk of MASLD progression and advancing precision-based approaches in metabolic liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04767-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:51:30Z","timestamp":1776055890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Asmaa Mohamed","family":"Fteah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Mamdouh","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Elrefaiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Abdel","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"4767_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"Z Younossi","year":"2023","unstructured":"Younossi Z, Golabi P, Paik J, et al. Global epidemiology of metabolic dysfunction\u2013associated steatotic liver disease and steatohepatitis. Hepatology. 2023a;77:1335\u201347.","journal-title":"Hepatology"},{"key":"4767_CR2","doi-asserted-by":"publisher","first-page":"e0251","DOI":"10.1097\/HC9.0000000000000251","volume":"7","author":"J Paik","year":"2023","unstructured":"Paik J, Henry L, Younossi Z, et al. The burden of metabolic dysfunction\u2013associated steatotic liver disease is rapidly growing worldwide from 1990 to 2019. Hepatol Commun. 2023;7:e0251.","journal-title":"Hepatol Commun"},{"issue":"1","key":"4767_CR3","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus on new fatty liver disease nomenclature. Ann Hepatol. 2023;29(1):101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133.","journal-title":"Ann Hepatol"},{"key":"4767_CR4","doi-asserted-by":"crossref","unstructured":"Alwahsh MS, Xu M, Itmezeh A, Kim M-H et al. (2025) Excessive intake of fructose and alcohol aggravates high-fat diet-induced steatohepatitis and changes hepatic iron homeostasis Histochem Cell Biol. 2025;163 (1):77.","DOI":"10.1007\/s00418-025-02402-4"},{"issue":"1","key":"4767_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jpn3.12219","volume":"79","author":"BJ Perumpail","year":"2024","unstructured":"Perumpail BJ, Manikat R, Wijarnpreecha K, et al. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis\/cirrhosis among adolescents\/young adults. J Pediatr Gastroenterol Nutr. 2024;79(1):110\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4767_CR6","doi-asserted-by":"publisher","first-page":"824776","DOI":"10.3389\/fmolb.2021.824776","volume":"8","author":"H Zhang","year":"2022","unstructured":"Zhang H, Su W, Xu H, Zhang X, Guan Y. HSD17B13: A potential therapeutic target for MASLD. Front Mol Biosci. 2022;8:824776. https:\/\/doi.org\/10.3389\/fmolb.2021.824776.","journal-title":"Front Mol Biosci"},{"key":"4767_CR7","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","volume":"21","author":"Z Younossi","year":"2023","unstructured":"Younossi Z, Wong G, Anstee Q, et al. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023b;21:1978\u201391.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4767_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"D Huang","year":"2023","unstructured":"Huang D, Wilson L, Behling C, et al. Fibrosis progression in biopsy-proven NAFLD among patients with and without diabetes. Gastroenterology. 2023;165:463\u2013e4725.","journal-title":"Gastroenterology"},{"key":"4767_CR9","doi-asserted-by":"publisher","first-page":"111648","DOI":"10.1016\/j.diabres.2024.111648","volume":"210","author":"Z Younossi","year":"2024","unstructured":"Younossi Z, Henry L. Epidemiology of MASLD\u2014focus on diabetes. Diabetes Res Clin Pract. 2024;210:111648.","journal-title":"Diabetes Res Clin Pract"},{"key":"4767_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"S Harrison","year":"2024","unstructured":"Harrison S, Bedossa P, Guy CD, et al. MAESTRO-MASH Investigators A phase 3, randomized, controlled trial of resmetiromin MASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med"},{"issue":"8","key":"4767_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ueg2.12534","volume":"12","author":"R Gallego-Dur\u00e1n","year":"2024","unstructured":"Gallego-Dur\u00e1n R, Ampuero J, Maya-Miles D, et al. Fibroblast growth factor-21 in MASLD progression. United Eur Gastroenterol J. 2024;12(8):1056\u201368. https:\/\/doi.org\/10.1002\/ueg2.12534.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"4767_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of NAFLD in Primary Care and Endocrinology Clinical Settings. Endocr Pract. 2022;28(5):528\u201362.","journal-title":"Endocr Pract"},{"issue":"4","key":"4767_CR13","doi-asserted-by":"publisher","first-page":"e1103","DOI":"10.1210\/clinem\/dgae341","volume":"110","author":"AW Potter","year":"2025","unstructured":"Potter AW, Chin GC, Looney DP, Friedl KE. Defining overweight and obesity by percent body fat instead of BMI. J Clin Endocrinol Metab. 2025;110(4):e1103\u20137. https:\/\/doi.org\/10.1210\/clinem\/dgae341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4767_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/medicina55050158","volume":"55","author":"D Hor\u00e1kov\u00e1","year":"2019","unstructured":"Hor\u00e1kov\u00e1 D, \u0160t\u011bp\u00e1nek L, Janout V, et al. Optimal HOMA-IR cut-offs in the Czech population. Med (Kaunas). 2019;55(5):158. https:\/\/doi.org\/10.3390\/medicina55050158.","journal-title":"Med (Kaunas)"},{"key":"4767_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2144\/01302tt01","volume":"30","author":"V Kristensen","year":"2001","unstructured":"Kristensen V, Kelefiotis D, Kristensen T, et al. High-throughput methods for detection of genetic variation. Biotechniques. 2001;30:318\u201322.","journal-title":"Biotechniques"},{"issue":"8","key":"4767_CR16","first-page":"391","volume":"44","author":"YH Chan","year":"2003","unstructured":"Chan YH. Biostatistics 102: Quantitative data \u2013 parametric & non-parametric tests. Singap Med J. 2003a;44(8):391\u20136.","journal-title":"Singap Med J"},{"issue":"10","key":"4767_CR17","first-page":"498","volume":"44","author":"YH Chan","year":"2003","unstructured":"Chan YH. Biostatistics 103: Qualitative data \u2013 tests of independence. Singap Med J. 2003b;44(10):498\u2013503.","journal-title":"Singap Med J"},{"issue":"12","key":"4767_CR18","first-page":"614","volume":"44","author":"YH Chan","year":"2003","unstructured":"Chan YH. Biostatistics 104: Correlational analysis. Singap Med J. 2003c;44(12):614\u20139.","journal-title":"Singap Med J"},{"issue":"4","key":"4767_CR19","first-page":"149","volume":"45","author":"YH Chan","year":"2004","unstructured":"Chan YH. Biostatistics 202: Logistic regression analysis. Singap Med J. 2004;45(4):149\u201353.","journal-title":"Singap Med J"},{"key":"4767_CR20","doi-asserted-by":"publisher","unstructured":"Samarasinghe SM, Anselmi L, Kumar R et al. (2023) Genetic and metabolic aspects of non-alcoholic fatty liver disease: implications of GCKR rs1260326 association with steatosis severity in Indian patients. J Med Hist Genet.; Article Collection 2023. https:\/\/doi.org\/10.1186\/s43042-023-00433-x","DOI":"10.1186\/s43042-023-00433-x"},{"issue":"1","key":"4767_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12902-024-01554-z","volume":"24","author":"M Zhang","year":"2024","unstructured":"Zhang M, Li X, Zhao Y, et al. Association between weight-adjusted waist index and non-alcoholic fatty liver disease: a population-based study. BMC Endocr Disord. 2024;24(1):15. https:\/\/doi.org\/10.1186\/s12902-024-01554-z.","journal-title":"BMC Endocr Disord"},{"key":"4767_CR22","doi-asserted-by":"publisher","unstructured":"Nisar T, Ahmad S, Riaz H et al. (2023) Prevalence of GCKR rs1260326 variant in subjects with obesity-associated NAFLD and T2DM: a case-control study in South Punjab, Pakistan. J Obes.;2023:6661858. https:\/\/doi.org\/10.1155\/2023\/6661858","DOI":"10.1155\/2023\/6661858"},{"key":"4767_CR23","doi-asserted-by":"publisher","unstructured":"Ramne S et al. (2024) Genetic variants at the FGF21 locus influence circulating FGF21 and metabolic traits. medRxiv. https:\/\/doi.org\/10.1101\/2024.01.01","DOI":"10.1101\/2024.01.01"},{"issue":"3","key":"4767_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cmet.2023.11.010","volume":"36","author":"C Singh","year":"2024","unstructured":"Singh C, Xiao Y, Fern\u00e1ndez-Hernando C, et al. ChREBP is activated by reductive stress and mediates GCKR GWAS traits such as increased hepatic fat, circulating FGF21, and circulating acylglycerols. Cell Metabol. 2024;36(3):144\u201358.","journal-title":"Cell Metabol"},{"key":"4767_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13679-025-00643-x","volume":"14","author":"I Filimidou","year":"2025","unstructured":"Filimidou I, et al. Circulating Fibroblast Growth Factor-21 in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Curr Obes Rep. 2025;14:51.","journal-title":"Curr Obes Rep"},{"issue":"16","key":"4767_CR26","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.3390\/ijms22168581","volume":"22","author":"GS Santiago-S\u00e1nchez","year":"2021","unstructured":"Santiago-S\u00e1nchez GS, Noriega-Rivera R, Hern\u00e1ndez-O\u2019Farrill E, Valiyeva F, Qui\u00f1ones-Diaz B, et al. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors. Int J Mol Sci. 2021;22(16):8581. https:\/\/doi.org\/10.3390\/ijms22168581.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04767-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:54:27Z","timestamp":1781646867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04767-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04767-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8643484\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to initiation of our case control study; the study protocol was reviewed and approved by the Institutional Review Board (IRB) of Theodor Bilharz Research Institute (TBRI) under approval number PT 784, following the ethical principles described by the 1975 Declaration of Helsinki and its later amendments.All participants voluntarily provided informed written consents prior to participation between October 2023 and September 2024 from specialized hepatology and gastroenterology inpatient departments, and outpatient clinics at TBRI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}